Gaseous mediator-based anti-inflammatory drugs

被引：17
|
作者：
Sulaieva, Oksana [1 ]
Wallace, John L. [2 ,3 ]
机构：
[1] Zaporozhye State Med Univ, Dept Histol, Zaporozhe, Ukraine
[2] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada
[3] Univ Camilo Castelo Branco, Fac Med, Sao Paulo, SP, Brazil
来源：
CURRENT OPINION IN PHARMACOLOGY | 2015年 / 25卷
基金：
加拿大健康研究院;
关键词：
SULFIDE-BASED THERAPEUTICS; PROTON PUMP INHIBITORS; MOLECULES CO-RMS; HYDROGEN-SULFIDE; NITRIC-OXIDE; CARBON-MONOXIDE; GASTROINTESTINAL SAFETY; COLORECTAL-CANCER; HEME OXYGENASE-1; MOUSE MODEL;
D O I：
10.1016/j.coph.2015.08.005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Among the most commonly used drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) remain problematic because of their propensity to cause serious adverse events, principally affecting the gastrointestinal tract. In recent years, the discovery of potent anti-inflammatory and cytoprotective effects of endogenous gaseous mediators (nitric oxide, hydrogen sulfide, carbon monoxide) stimulated efforts to develop novel, combination NSAIDs that suppress prostaglandin synthesis (producing anti-inflammatory and analgesic effects) and release one or more of the cytoprotective gaseous mediators. Gaseous mediator-based anti-inflammatory drugs have reached the human clinical trial stage and show considerable promise as a safer option for treating chronic inflammatory diseases.
引用
收藏
页码：1 / 6
页数：6
相关论文
共 50 条
12345